What is the maximum recommended dose of trazodone for treating insomnia in an 82‑year‑old female?

Maximum Trazodone Dose for Insomnia in an 82-Year-Old Female

Trazodone should not be used for insomnia in this patient, as major clinical guidelines explicitly advise against its use for chronic insomnia disorder due to lack of efficacy on objective sleep measures and concerning adverse effects, particularly in older adults. 1

Guideline-Based Recommendation

The 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guidelines specifically advise against use of trazodone for treatment of chronic insomnia disorder. 1 This recommendation was based on systematic reviews showing:

• No differences in sleep efficiency or discontinuation rates between trazodone (50-150 mg) and placebo 1
• No improvements in objective sleep measures including sleep onset latency, total sleep time, or wake after sleep onset 1
• Only marginal improvement in subjective sleep quality 1
• Low-quality evidence with very short study durations (mean 1.7 weeks) and follow-up of only 1-4 weeks 1
• Adverse effect profile that outweighs limited benefits 1

Critical Safety Concerns in Older Adults

Falls and Cognitive Impairment

• Falls were the most frequent adverse event (30% of participants) in older adults using trazodone in long-term care facilities 2
• Older adults are particularly vulnerable to orthostatic hypotension, arrhythmias, and cognitive impairment with trazodone 3

Anticholinergic Effects

• The 2019 Beers Criteria carry strong recommendations to avoid medications with antimuscarinic effects in older adults 1
• Trazodone's adverse effect profile is particularly concerning in the geriatric population 1

FDA-Approved Dosing (If Used Despite Guidelines)

If trazodone is prescribed off-label for insomnia despite guideline recommendations, the FDA labeling provides the following information for depression treatment (noting trazodone is NOT FDA-approved for insomnia): 4

• Initial dose: 150 mg/day in divided doses 4
• Dose titration: May increase by 50 mg/day every 3-4 days 4
• Maximum for outpatients: Usually should not exceed 400 mg/day in divided doses 4
• Maximum for inpatients: Up to but not exceeding 600 mg/day in divided doses 4

Practical Dosing for Insomnia (Off-Label)

Research studies examining trazodone for insomnia used:

• Dose range: 50-150 mg before bedtime 1
• Elderly-specific maximum: 300-400 mg/day total (lower than younger patients who tolerate up to 600 mg/day) 3
• Common practice: 150 mg predominantly at bedtime, increased as needed to 200-300 mg 5

Alternative Recommendations

Instead of trazodone, consider:

First-Line Options

• Cognitive behavioral therapy for insomnia (CBT-I) as the preferred initial treatment 1
• Low-dose doxepin (3-6 mg) showed improved outcomes in older adults with better tolerability 1

Second-Line Pharmacologic Options

• Nonbenzodiazepine BZRAs (zolpidem, zaleplon, eszopiclone) at lowest effective doses for shortest duration, though FDA warnings exist regarding serious injuries from sleep behaviors 1
• These should be used with extreme caution and counseling about risks 1

Common Pitfalls to Avoid

• Do not assume trazodone is safe simply because it is commonly prescribed - its widespread off-label use for insomnia does not reflect evidence-based practice 6
• Do not use doses studied for depression (150-600 mg) when treating insomnia, as lower doses (50-150 mg) are typically used off-label 1
• Do not overlook fall risk assessment in this 82-year-old patient before prescribing any sedating medication 2
• Do not ignore drug interactions - consider dose reduction with strong CYP3A4 inhibitors 4

Clinical Context

While trazodone remains one of the most commonly prescribed medications for insomnia in clinical practice 7, 6, this widespread use contradicts current evidence-based guidelines 1. The majority of sleep medicine experts and clinical guideline panels agree that trazodone should not be first-line therapy for insomnia 6. In an 82-year-old woman, the risks of falls, orthostatic hypotension, and cognitive effects are particularly concerning and likely outweigh any modest subjective sleep quality improvements 1, 2.